PT2205635T - Proteínas de ligação a antigénio capazes de se ligarem a linfopoietina do estroma tímico - Google Patents

Proteínas de ligação a antigénio capazes de se ligarem a linfopoietina do estroma tímico

Info

Publication number
PT2205635T
PT2205635T PT88303623T PT08830362T PT2205635T PT 2205635 T PT2205635 T PT 2205635T PT 88303623 T PT88303623 T PT 88303623T PT 08830362 T PT08830362 T PT 08830362T PT 2205635 T PT2205635 T PT 2205635T
Authority
PT
Portugal
Prior art keywords
proteins capable
thymic stromal
stromal lymphopoietin
binding
antigen binding
Prior art date
Application number
PT88303623T
Other languages
English (en)
Portuguese (pt)
Inventor
R Comeau Michael
f smothers James
Mehlin Christopher
P Yoon Bo-Rin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40242598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2205635(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT2205635T publication Critical patent/PT2205635T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT88303623T 2007-09-10 2008-09-09 Proteínas de ligação a antigénio capazes de se ligarem a linfopoietina do estroma tímico PT2205635T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10
US9167608P 2008-08-25 2008-08-25

Publications (1)

Publication Number Publication Date
PT2205635T true PT2205635T (pt) 2016-07-13

Family

ID=40242598

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88303623T PT2205635T (pt) 2007-09-10 2008-09-09 Proteínas de ligação a antigénio capazes de se ligarem a linfopoietina do estroma tímico

Country Status (36)

Country Link
US (6) US7982016B2 (cg-RX-API-DMAC7.html)
EP (3) EP3524622A1 (cg-RX-API-DMAC7.html)
JP (8) JP5956716B2 (cg-RX-API-DMAC7.html)
KR (2) KR20140141666A (cg-RX-API-DMAC7.html)
CN (2) CN101809035B (cg-RX-API-DMAC7.html)
AR (1) AR068508A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008300028B2 (cg-RX-API-DMAC7.html)
CA (1) CA2698382C (cg-RX-API-DMAC7.html)
CL (2) CL2008002668A1 (cg-RX-API-DMAC7.html)
CR (2) CR11319A (cg-RX-API-DMAC7.html)
CY (2) CY1117702T1 (cg-RX-API-DMAC7.html)
DK (1) DK2205635T3 (cg-RX-API-DMAC7.html)
EA (2) EA201590631A1 (cg-RX-API-DMAC7.html)
ES (1) ES2581229T3 (cg-RX-API-DMAC7.html)
FR (1) FR22C1059I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20160638T1 (cg-RX-API-DMAC7.html)
HU (2) HUE028361T2 (cg-RX-API-DMAC7.html)
IL (3) IL204069A (cg-RX-API-DMAC7.html)
JO (1) JO3351B1 (cg-RX-API-DMAC7.html)
LT (2) LT2205635T (cg-RX-API-DMAC7.html)
LU (1) LUC00289I2 (cg-RX-API-DMAC7.html)
MX (1) MX2010002590A (cg-RX-API-DMAC7.html)
MY (1) MY150242A (cg-RX-API-DMAC7.html)
NL (1) NL301207I2 (cg-RX-API-DMAC7.html)
NO (1) NO2022055I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ583933A (cg-RX-API-DMAC7.html)
PE (2) PE20110668A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501025B1 (cg-RX-API-DMAC7.html)
PL (1) PL2205635T3 (cg-RX-API-DMAC7.html)
PT (1) PT2205635T (cg-RX-API-DMAC7.html)
RS (1) RS54950B1 (cg-RX-API-DMAC7.html)
SG (2) SG178781A1 (cg-RX-API-DMAC7.html)
SI (1) SI2205635T1 (cg-RX-API-DMAC7.html)
TW (2) TWI449709B (cg-RX-API-DMAC7.html)
WO (1) WO2009035577A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201001895B (cg-RX-API-DMAC7.html)

Families Citing this family (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
EP2803675A3 (en) * 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
EP3594356A1 (en) * 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
AU2011305306C1 (en) * 2010-09-22 2016-02-18 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2013067051A1 (en) * 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Biomarkers for tslp treatment
KR20180137614A (ko) * 2012-04-27 2018-12-27 노보 노르디스크 에이/에스 사람 cd30 리간드 항원 결합 단백질
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3041863A4 (en) 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015118124A1 (en) * 2014-02-06 2015-08-13 Vib Vzw Thymic stromal lymphopoietin receptor antagonist
CA3193070A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
MX377275B (es) 2014-05-16 2025-03-07 Amgen Inc Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
KR20170016335A (ko) 2014-06-03 2017-02-13 암겐 인코포레이티드 약물 전달 디바이스의 사용자를 보조하기 위한 디바이스들 및 방법들
MX392725B (es) 2014-10-14 2025-03-24 Amgen Inc Dispositivo de inyeccion de farmaco con indicadores visuales y audibles.
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP3233159B1 (en) 2014-12-19 2020-03-04 Amgen Inc. Drug delivery device with live button or user interface field
AU2016220141B2 (en) 2015-02-17 2018-07-12 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en) 2015-02-27 2021-12-15 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
UY36578A (es) * 2015-03-11 2016-09-30 Glaxosmithkline Ip Dev Ltd Proteínas de unión a tslp
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
UY36889A (es) * 2015-09-09 2017-04-28 Novartis Ag Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
KR20180042433A (ko) 2015-09-09 2018-04-25 노파르티스 아게 흉선 기질 림포포이에틴 (tslp)-결합 항체 및 항체의 사용 방법
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
GB201615588D0 (en) * 2016-09-14 2016-10-26 Glaxosmithkline Ip Dev Ltd TSLP Binding Proteins
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
US11001624B2 (en) * 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988B1 (en) 2016-05-16 2023-10-18 Amgen Inc. Data encryption in medical devices with limited computational capability
EP3465124A1 (en) 2016-06-03 2019-04-10 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
TWI802193B (zh) 2016-06-14 2023-05-11 美商默沙東有限責任公司 抗凝血因子ｘｉ抗體
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US10919966B2 (en) * 2016-08-05 2021-02-16 Y-Biologics Inc. Antibody to programmed death-ligand 1 (PD-L1) and use thereof
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019008432A (es) 2017-01-17 2019-11-18 Amgen Inc Dispositivos de inyeccion y metodos relacionados de uso y ensamblaje.
PL3383916T3 (pl) * 2017-01-24 2023-06-12 I-Mab Biopharma Us Limited Przeciwciała anty-cd73 i ich zastosowania
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
EP3592402A1 (en) 2017-03-07 2020-01-15 Amgen Inc. Needle insertion by overpressure
EP3592404A1 (en) 2017-03-09 2020-01-15 Amgen Inc. Insertion mechanism for drug delivery device
EP3596225A1 (en) 2017-03-14 2020-01-22 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
EP4241807B1 (en) 2017-03-28 2025-02-19 Amgen Inc. Plunger rod and syringe assembly system
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MA48464A (fr) 2017-04-28 2020-03-04 Amgen Inc Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018282077B2 (en) 2017-06-08 2023-11-23 Amgen Inc. Torque driven drug delivery device
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
CN109206514B (zh) * 2017-07-03 2019-10-08 拜西欧斯（北京）生物技术有限公司 Tslp单克隆抗体及其制备方法和应用
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
EP3658203B2 (en) 2017-07-25 2025-10-01 Amgen Inc. Drug delivery device with gear module and related method of assembly
KR102577670B1 (ko) 2017-08-01 2023-09-12 암젠 인크 샘플의 실시간 글리칸 분석을 수행하기 위한 시스템 및 방법
WO2019028187A1 (en) 2017-08-01 2019-02-07 Amgen Inc. SYSTEMS AND METHODS FOR REAL-TIME PREPARATION OF A POLYPEPTIDE SAMPLE FOR MASS SPECTROMETRY ANALYSIS
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3669004A1 (en) 2017-08-16 2020-06-24 Medimmune, LLC Compositions and methods for treatment of atopic dermatitis and treatment selection
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
IL272636B2 (en) 2017-10-06 2024-10-01 Amgen Inc Drug delivery device with interlock assembly and related method of assembly
IL273323B2 (en) 2017-10-09 2024-10-01 Amgen Inc Drug delivery device with drive assembly and related assembly method
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
EP3707075A1 (en) 2017-11-06 2020-09-16 Amgen Inc. Fill-finish assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
CN111225696B (zh) 2017-11-10 2023-07-18 安进公司 用于药物递送装置的柱塞
WO2019099324A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Door latch mechanism for drug delivery device
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
WO2019178280A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Sequential digestion of polypeptides for mass spectrometric analysis
CN111954719B (zh) 2018-03-26 2025-07-18 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
SG11202011330PA (en) 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
MA53724A (fr) 2018-09-24 2021-12-29 Amgen Inc Systèmes et procédés de dosage interventionnel
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3110371A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
AU2019352616B2 (en) 2018-10-02 2024-10-10 Amgen Inc. Injection systems for drug delivery with internal force transmission
TW202529830A (zh) 2018-10-05 2025-08-01 美商安進公司 具有劑量指示器之藥物遞送裝置
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US12000775B2 (en) 2018-12-14 2024-06-04 Amgen Inc. System suitability method for use with protein concentration determination by slope
US11452738B2 (en) 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
WO2020168156A1 (en) 2019-02-14 2020-08-20 Amgen Inc. Systems and methods for preparing a sample and performing a real-time assay of the sample
US12493019B2 (en) 2019-02-20 2025-12-09 Amgen Inc. Methods of determining protein stability
JP7570341B2 (ja) 2019-03-04 2024-10-21 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
EP3948242A1 (en) 2019-03-27 2022-02-09 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
CN116751295A (zh) 2019-06-04 2023-09-15 江苏恒瑞医药股份有限公司 能结合胸腺基质淋巴细胞生成素的抗体及其应用
EP4517327A3 (en) 2019-06-05 2025-05-07 Amgen Inc. Methods of identifying attributes of therapeutic proteins
CA3147044A1 (en) 2019-07-11 2021-01-14 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
WO2021041067A2 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
IL292437A (en) 2019-10-28 2022-06-01 Medimmune Ltd Dry powder formulations of antibodies that bind thymic lymphopoietin (tslp) and methods of using them
CN114887053A (zh) * 2019-11-29 2022-08-12 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
US20220363781A1 (en) * 2019-12-13 2022-11-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN111171150B (zh) * 2020-02-05 2020-12-08 北京智仁美博生物科技有限公司 抗人tslp抗体及其用途
EP4103605A1 (en) 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
AU2021219839A1 (en) 2020-02-13 2022-08-25 Amgen Inc. Formulations of human anti-TSLP antibodies and methods of treating inflammatory disease
JP2023513833A (ja) 2020-02-18 2023-04-03 アムジェン インコーポレイテッド ヒト抗ｔｓｌｐ抗体の製剤及びそれを使用する方法
CN111662379B (zh) * 2020-05-09 2021-03-02 江苏省疾病预防控制中心(江苏省公共卫生研究院) 抗新型冠状病毒的抗体、制备方法和应用
JP2023526469A (ja) * 2020-05-20 2023-06-21 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ＳＡＲＳ－ＣｏＶ－２に対する強力な中和抗体、その生成および使用
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023003164A (es) 2020-09-18 2023-05-04 Amgen Inc Metodos de procesamiento de una muestra para analisis de mapeo de peptidos.
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
MX2023005320A (es) 2020-11-05 2023-05-19 Amgen Inc Materiales y metodos para el procesamiento de proteinas.
CN114437212B (zh) * 2020-11-06 2023-03-14 上海麦济生物技术有限公司 抗人胸腺基质淋巴细胞生成素抗体及其制备方法和应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
KR20230140571A (ko) * 2021-02-04 2023-10-06 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 흉선 기질 림포포이에틴을 특이적으로 인식하는 항체 및 이의 용도
IL307439A (en) 2021-04-23 2023-12-01 Amgen Inc Different anti-TSLP antibodies
BR112023021867A2 (pt) 2021-04-23 2023-12-19 Amgen Inc Composições de anticorpo anti-tslp e seus usos
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container
AU2022285961A1 (en) * 2021-05-30 2023-12-14 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN113069543B (zh) * 2021-06-07 2021-08-06 迈威(上海)生物科技股份有限公司 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
WO2023059607A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023070948A1 (zh) * 2021-11-01 2023-05-04 江苏荃信生物医药股份有限公司 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的浓缩溶液的制备方法及液体制剂
CA3237662A1 (en) 2021-11-09 2023-05-19 Amgen Inc. Production of therapeutic proteins
CN116217724B (zh) * 2021-12-02 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN114369654B (zh) * 2021-12-21 2023-11-07 广州市妇女儿童医疗中心 川崎病的生物标志物及其应用
IL313679A (en) * 2021-12-24 2024-08-01 Inmagene Pte Ltd Novel anti-tslp antibodies
MX2024010773A (es) * 2022-03-03 2024-09-10 Pfizer Anticuerpos multiespecificos y usos de estos.
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US12110324B2 (en) * 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
CN118772266B (zh) * 2022-10-21 2025-06-17 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
UY40500A (es) 2022-10-26 2024-04-30 Amgen Inc Composiciones de anticuerpos anti-tslp y usos de las mismas
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
CN120659807A (zh) * 2023-02-23 2025-09-16 四川科伦博泰生物医药股份有限公司 一种靶向tslp的单克隆抗体制剂
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
TW202509066A (zh) 2023-05-18 2025-03-01 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療皮質類固醇依賴性氣喘
WO2024259275A1 (en) 2023-06-14 2024-12-19 Bristol-Myers Squibb Company Near real time sialic acid quantitation of glycoproteins
WO2024264003A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind interleukin 13 and tslp or tslpr and methods of use
WO2024264002A2 (en) * 2023-06-22 2024-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and tslpr and methods of use
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
TW202530266A (zh) * 2023-10-12 2025-08-01 大陸商信達生物製藥（蘇州）有限公司 抗ＩＬ－４Ｒα抗體及其用途
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58117537A (ja) 1982-01-06 1983-07-13 Toray Ind Inc 感光性樹脂組成物
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2033082A1 (en) 1989-06-15 1990-12-16 Linda S. Park Interleukin-7 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP1897949B1 (en) 1998-09-21 2014-11-12 Merck Sharp & Dohme Corp. Human interleukin-B50. Therapeutic uses
US20030099947A1 (en) 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
IL143034A0 (en) * 1998-11-13 2002-04-21 Immunex Corp Human tslp dna and polypeptides
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
AU2001259758A1 (en) 2000-05-12 2001-11-26 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
AU2001271624A1 (en) 2000-06-28 2002-01-08 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1234728C (zh) * 2001-05-16 2006-01-04 上海睿星基因技术有限公司 新的人淋巴因子、其编码序列及用途
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
DK1417231T3 (da) * 2001-07-23 2013-07-22 Immunex Corp Modificeret human thymisk stromal lymphopoietin
PT2311869E (pt) * 2002-02-01 2013-03-04 Merck Sharp & Dohme Utilização de reagentes relacionados com citoquinas de mamíferos
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
NZ538569A (en) 2002-09-06 2009-02-28 Amgen Inc Therapeutic human anti-IL-1R1 monoclonal antibody
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
AU2004257781B2 (en) 2003-07-18 2009-07-16 Merck Sharp & Dohme Corp. Treatment and diagnosis of neoplasms using Thymic Stromal Lymphopoietin
AU2004309347B2 (en) 2003-12-19 2010-03-04 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
AU2005307831A1 (en) * 2004-11-17 2006-05-26 Amgen, Inc. Fully human monoclonal antibodies to IL-13
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
EP1981912A2 (en) 2006-01-13 2008-10-22 Irm, Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
EP2170957A1 (en) 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
EP2205635A1 (en) 2010-07-14
PH12017501025B1 (en) 2022-10-26
US8163284B2 (en) 2012-04-24
CA2698382A1 (en) 2009-03-19
IL204069A (en) 2017-03-30
HUE028361T2 (en) 2016-12-28
IL250900A0 (en) 2017-04-30
CY2022036I1 (el) 2023-01-05
AU2008300028A1 (en) 2009-03-19
HK1145843A1 (zh) 2011-05-06
TW201412774A (zh) 2014-04-01
LTC2205635I2 (cg-RX-API-DMAC7.html) 2025-10-27
RS54950B1 (sr) 2016-11-30
TW200918554A (en) 2009-05-01
FR22C1059I1 (fr) 2023-02-03
JP5956716B2 (ja) 2016-07-27
CN104231081A (zh) 2014-12-24
ZA201001895B (en) 2011-02-23
EP3524622A1 (en) 2019-08-14
PE20140232A1 (es) 2014-02-28
US10287348B2 (en) 2019-05-14
JP2017110011A (ja) 2017-06-22
PH12017501025A1 (en) 2018-01-29
HRP20160638T1 (hr) 2016-07-01
CL2012003245A1 (es) 2013-03-22
AU2008300028B2 (en) 2014-12-18
US9284372B2 (en) 2016-03-15
US20160152700A1 (en) 2016-06-02
EP2703414A1 (en) 2014-03-05
EP2205635B1 (en) 2016-05-25
JP2020058365A (ja) 2020-04-16
SI2205635T1 (sl) 2016-09-30
CA2698382C (en) 2015-07-14
EA201590631A1 (ru) 2016-03-31
JP2024161358A (ja) 2024-11-19
SG10201506251YA (en) 2015-11-27
KR20140141666A (ko) 2014-12-10
LUC00289I2 (cg-RX-API-DMAC7.html) 2025-05-12
KR101597371B1 (ko) 2016-02-26
SG178781A1 (en) 2012-03-29
PE20110668A1 (es) 2011-10-01
FR22C1059I2 (fr) 2023-12-22
JP2023065375A (ja) 2023-05-12
US7982016B2 (en) 2011-07-19
CR11319A (es) 2010-04-21
US20120190829A1 (en) 2012-07-26
JP2010538608A (ja) 2010-12-16
MX2010002590A (es) 2010-03-26
HUS2200051I1 (hu) 2022-12-28
US20200071393A1 (en) 2020-03-05
JP2019038843A (ja) 2019-03-14
JP2021191758A (ja) 2021-12-16
CN104231081B (zh) 2022-01-11
TWI449709B (zh) 2014-08-21
ES2581229T3 (es) 2016-09-02
JP2015091820A (ja) 2015-05-14
CY2022036I2 (el) 2023-03-24
LT2205635T (lt) 2016-09-26
AR068508A1 (es) 2009-11-18
EA022796B1 (ru) 2016-03-31
CY1117702T1 (el) 2017-05-17
CN101809035A (zh) 2010-08-18
CL2008002668A1 (es) 2009-08-14
CR20150095A (es) 2015-04-06
KR20100067660A (ko) 2010-06-21
CN101809035B (zh) 2014-07-09
EA201000471A1 (ru) 2010-10-29
US20110274687A1 (en) 2011-11-10
NL301207I1 (nl) 2022-12-21
LTPA2022016I1 (cg-RX-API-DMAC7.html) 2023-01-10
NO2022055I1 (no) 2022-12-09
WO2009035577A1 (en) 2009-03-19
US20250154241A1 (en) 2025-05-15
NL301207I2 (nl) 2023-02-02
MY150242A (en) 2013-12-31
PL2205635T3 (pl) 2016-12-30
DK2205635T3 (en) 2016-07-18
JO3351B1 (ar) 2019-03-13
US20090238823A1 (en) 2009-09-24
NZ583933A (en) 2012-07-27
IL265854A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
IL265854A (en) Antigen binding proteins capable of binding thymic subset of lymphopoietin
IL232008A (en) Protein isolate heterodimer alpha-4-in-cell-7-specific antigen-binding and various aspects thereof
IL206188A0 (en) Antigen binding proteins
IL193229A0 (en) Thymic stromal lymphopoietin (tslp) antibodies and uses thereof
ZA201001541B (en) Human c-fms antigen binding proteins
GB2461546B (en) Antigen binding polypeptides
ZA201100058B (en) Prostaglandin e2 binding proteins and uses thereof
ZA201002160B (en) Human gm-csf antigen binding proteins
EP2069401A4 (en) MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
IL205569A0 (en) Wise binding antibodies and epitopes
IL220398A (en) Proteins bind to heterodimers and use them
IL216266A0 (en) Bispecific antigen binding proteins
SG10201401681PA (en) Novel antigen binding proteins
ZA201003131B (en) Anti-rsv g protein antibodies
ZA200904152B (en) Canine thymic stromal lymphopoietin protein and uses thereof
GB0718843D0 (en) Materials and methods relating to modifying the binding of antibodies
IL182717A0 (en) Antibodies to interferon - ??/?? binding protein
HK1147763A (en) Antigen binding proteins
IL210002A0 (en) Antigen binding polypeptides
HK1138012A (en) Canine thymic stromal lymphopoietin protein and uses thereof